Proteros Biostructures and Boehringer Ingelheim Pharmaceuticals Enter into Protein Crystallography Agreement.MARTINSRIED, Germany & RIDGEFIELD, Conn. -- Proteros biostructures GmbH announced today that it has entered into a research collaboration with Boehringer Ingelheim Pharmaceuticals, Inc. in the field of protein crystallography. Under the terms of the agreement, which will run for 18 months, Proteros will receive research funding Research funding is a term generally covering any funding for scientific research, in the areas of both "hard" science and technology and social science. The term often connotes funding obtained through a competitive process, in which potential research projects are evaluated and fees and success payments for the generation and analyses of protein-ligand-structures of hits and evolved chemical entities from in-house In-house In the context of general equities, keeping an activity within the firm. For example, rather than go to the marketplace and sell a security for a client to anyone, an attempt is made to find a buyer to complete the transaction with the firm. Boehringer Ingelheim programs. Proteros will apply its proprietary Free Mounting System (FMS FMS - Flexible Manufacturing System (factory automation). (TM)) and Picodropper(TM) technologies to maximize data quality and success rates, thus allowing rapid evolution of multiple hit series at Boehringer Ingelheim. Financial details of the transaction were not disclosed. Torsten Neuefeind, Ph.D., Chief Executive Officer of Proteros, stated, "We are pleased to extend the scope of our long standing relationship with various sites of Boehringer Ingelheim. By taking advantage of Proteros' experience and the industrialized in·dus·tri·al·ize v. in·dus·tri·al·ized, in·dus·tri·al·iz·ing, in·dus·tri·al·iz·es v.tr. 1. To develop industry in (a country or society, for example). 2. processes enabling time- and cost-efficient protein-ligand-structure analyses, Boehringer Ingelheim complements its internal capabilities with our external expertise and access flexible resources. Especially when working with challenging chemical entities, Proteros' Picodropper(TM) can make the difference between success and failure. This collaboration underscores Proteros' expertise in the field of protein crystallography, and furthermore marks an important milestone in Proteros' progress to further expand its client base in North America North America, third largest continent (1990 est. pop. 365,000,000), c.9,400,000 sq mi (24,346,000 sq km), the northern of the two continents of the Western Hemisphere. ." Proteros biostructures GmbH: Proteros biostructures is a privately held company privately held company A firm whose shares are held within a relatively small circle of owners and are not traded publicly. , which provides services and unique technologies for X-ray X-ray Electromagnetic radiation of extremely short wavelength (100 nanometres to 0.001 nanometre) produced by the deceleration of charged particles or the transitions of electrons in atoms. protein structure analysis to the life science industries. Proteros accelerates and improves structure analysis and structure-based drug discovery by its expertise and unique technologies. The Picodropper[TM] technology was developed in order to improve the success rates of protein-ligand-complex structure analysis, namely produce co-crystals with ligands of poor solubility solubility Degree to which a substance dissolves in a solvent to make a solution (usually expressed as grams of solute per litre of solvent). Solubility of one fluid (liquid or gas) in another may be complete (totally miscible; e.g. or low affinity which can otherwise not be obtained, e.g. by soaking methods or classical co-crystallization. This advantageous technology is available to Proteros' customers under all types of service agreements. More information about Proteros can be found on the company's website at www.proteros.com. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion